Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial-Reference-Cited by-同舟云学术

Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

Published:2017-02-07 Issue:5 Volume:109 Page:
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Allen Carl E.¹,Laetsch Theodore W.¹,Mody Rajen¹,Irwin Meredith S.¹,Lim Megan S.¹,Adamson Peter C.¹,Seibel Nita L.¹,Parsons D. Williams¹,Cho Y. Jae¹,Janeway Katherine¹,

Affiliation:

1. Affiliations of authors: Texas Children’s Cancer Center, Texas Children’s Hospital, Houston, TX (CEA, DWP); Division of Pediatric Hematology-Oncology, Department of Pediatrics (CEA, DWP), Department of Molecular and Human Genetics (DWP), and Human Genome Sequencing Center (DWP), Baylor College of Medicine, Houston, TX; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern

Funder

National Cancer Institute

NCI National Clinical Trials Network

Pediatric NCI Molecular Analysis for Therapeutic Choice Trial

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/109/5/djw274/25422352/djw274.pdf

Reference139 articles.

1. Recurrent BRAF mutations in Langerhans cell histiocytosis;Badalian-Very;Blood,2010

2. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth;Mody;JAMA.,2015

3. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma;Perry;Proc Natl Acad Sci U S A,2014

4. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations;Pugh;Nature.,2012

5. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models;Taylor;J Clin Invest.,2009

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial;International Journal of Clinical Oncology;2023-12-19

2. Precision Oncology in Pediatric Cancer Surgery;Surgical Oncology Clinics of North America;2023-12

3. Novel therapeutic approaches for pediatric diencephalic tumors: improving functional outcomes;Frontiers in Oncology;2023-10-10

4. Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma;eJHaem;2023-09-07

5. Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies;Clinical Pharmacology & Therapeutics;2023-07-25